Johnson & Johnson projects $2.5 billion from vaccine sales globally

Johnson & Johnson on Wednesday said that it anticipates $2.5 billion in annual sales of its COVID-19 vaccine, even as the company faces questions about the vaccine’s effectiveness with the delta variant.The forecasted sales…